Godavari Drugs share price
BSE: 530317Pharmaceuticals & BiotechnologySmall Cap
Godavari Drugs Ltd. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995
Last close ₹123.20up ₹2.20 (1.82%)
Share price at the BSE close on 29 Oct 2026. Previous close ₹121.00.
29 Oct: open ₹122.20, high ₹124.60, low ₹122.20
52-week range of traded prices to 29 Oct 2026
₹69.70Low, 9 Dec 2025₹144.35High, 12 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹125 Cr3,042nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 30.01
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.65
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 4.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.01
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 6,505
Results
Standalone; ₹ crore.Godavari Drugs quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +4.8%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +9.7%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹28 Crdown 15.70%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹1.11 Crdown 14.08%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 4.0%
Revenue by quarter
Peak revenue ₹33 Cr, quarter to Mar 2026; lowest ₹22 Cr, quarter to Dec 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.1 | 29.6 | 25.5 | 23.8 | 26.6 | 22.2 | 33.2 | 28.0 |
| Net profit | 1.1 | 0.8 | 0.9 | 1.0 | 1.0 | 0.8 | 1.3 | 1.1 |
| Net margin | 4.2% | 2.6% | 3.5% | 4.4% | 3.8% | 3.4% | 3.9% | 4.0% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹106 Crdown 6.65%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹4.09 Crdown 6.64%
- Net margin
- 3.9%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2018, GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 83what Revenue, Mar 2017, includes. This period's revenue includes excise duty of ₹7.28 crore, a tax on the goods the company makes that it collects and pays to the government. | 64 | 84 | 96 | 123 | 161 | 160 | 157 | 113 | 106 |
| Net profit | 2 | 1 | 1 | 2 | 4 | 5 | 4 | 6 | 4 | 4 |
| Net margin | 2.2% | 1.3% | 1.4% | 2.1% | 3.4% | 3.3% | 2.4% | 3.5% | 3.9% | 3.9% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceticals, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record. Its history crosses a change of basis in the accounts in the year to Mar 2018: days before it are of the company before the change.Godavari Drugs PE ratio and valuation
Price to earnings
At or below today's level on 97% of 2,312 trading days since Jun 2017.
LowestHighest
Its median14.76Industry median28.22
Price to book
At or below today's level on 51% of 1,943 trading days since Nov 2018.
LowestHighest
Its median1.64Industry median2.99
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −1.6% | −30.6% | +41.7% | 0.0% |
| 3 years | +4.3% | −7.0% | +12.2% | 0.0% |
| 5 years | +13.5% | −5.9% | +20.6% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Godavari Drugs insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 10 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Godavari Drugs competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Godavari Drugs in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Bal PharmaBALPHARMA | 135 | 18.69 | 1.64 | +13.5% | +1.3% | 9.0% | 9.3% | 1.42% |
 Panchsheel OrganicPANCHSHEEL | 133 | 12.94 | 0.95 | +2.3% | – | 7.5% | 7.3% | 3.16% |
 Parnax LabPARNAXLAB | 126 | 14.07 | 1.32 | +31.9% | −17.3% | 10.0% | 9.3% | 0.00% |
 Krebs Biochemicals and IndustriesKREBSBIO | 125 | – | – | −1.3% | – | – | −14.3% | 0.00% |
 Speciality MedicinesSPML | 125 | 9.57 | 1.75 | – | – | 18.3% | – | 0.00% |
 Sotac PharmaceuticalsSOTAC | 118 | 20.38 | 2.00 | +0.1% | −28.2% | 10.3% | – | 0.19% |
 Makers LaboratoriesMAKERSL | 114 | 33.21 | 1.56 | +17.6% | −61.6% | 4.8% | 11.1% | 0.00% |
 Alpa LaboratoriesALPA | 111 | – | 0.59 | +0.5% | – | – | −1.8% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Godavari Drugs announcements
Oct 2026
16 Oct · Intimation Regarding Change In The Corporate Identification Number (CIN) Of The Company Consequent Upon Alteration Of The Object Clause Of The Memorandum Of Association
Sep 2026
25 Sep · Meeting
3 Sep · Intimation Of Dispatch Of Physical Letters Pursuant To Regulation 36(1)(B) Of The SEBI (LODR) Regulations
Godavari Drugs share price by year
Each calendar year to 2025.Godavari Drugs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 76.83 | −29.7% | 112.75 | 70.24 |
| 2024 | 109.35 | +21.4% | 147.75 | 90.46 |
| 2023 | 90.06 | −5.1% | 109.75 | 74.75 |
| 2022 | 94.90 | +51.5% | 94.95 | 52.20 |
| 2021 | 62.65 | +79.0% | 80.25 | 38.25 |
| 2020 | 35.00 | +119.4% | 40.55 | 10.35 |
| 2019 | 15.95 | −32.1% | 24.25 | 14.10 |
| 2018 | 23.50 | −42.3% | 43.40 | 20.80 |
| 2017 | 40.75 | −1.1% | 46.40 | 31.80 |
| 2016 | 41.20 | −36.0% | 64.95 | 32.60 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 28 Oct 2026 | 119.90 | 121.00 | 116.50 | 121.00 | 119.64 | 1,106 |
| 27 Oct 2026 | 120.00 | 120.00 | 117.00 | 119.90 | 118.54 | 3,619 |
| 26 Oct 2026 | 121.10 | 122.40 | 120.00 | 122.40 | 120.12 | 1,338 |
| 23 Oct 2026 | 121.00 | 123.00 | 120.00 | 120.50 | 120.23 | 6,422 |
| 22 Oct 2026 | 125.00 | 125.50 | 120.00 | 124.15 | 123.45 | 13,601 |
| 21 Oct 2026 | 122.50 | 125.30 | 113.20 | 121.95 | 117.86 | 10,670 |
| 19 Oct 2026 | 128.00 | 128.05 | 119.45 | 122.55 | 123.57 | 14,197 |
| 16 Oct 2026 | 129.80 | 134.00 | 129.40 | 133.40 | 130.85 | 1,065 |
| 15 Oct 2026 | 135.00 | 135.00 | 128.50 | 129.80 | 131.55 | 4,412 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 530317
- ISIN
- INE362C01012
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.godavaridrugs.com
- CIN
- L24230TG1987PLC008016
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1987
- Registered office
- Mayfair, S P Road, Secunderabad 500003, Telangana
- Share registrar
- CIL Securities Ltd
- Keeps the register of shareholders and handles transfers and dividend payments